Logo

BillionToOne Unity Prenatal Screen

Jun 28, 2019

BillionToOne has commercially launched its Unity prenatal screening assay. According to BillionToOne, the assay is powered by its molecular counting technology and is the only prenatal screen that tests cell-free fetal DNA for cystic fibrosis, spinal muscular atrophy, and sickle cell disease using only one tube of the mother's blood. The firm said it will make the test available at select clinics through its early access program, with plans for a broader commercial launch later this year. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.